Compare Ascendis Pharma A/S (ASND) vs Vanguard Mega Cap Growth ETF (MGK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Vanguard Mega Cap Growth ETF — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Vanguard Mega Cap Growth ETF trades at $88.55. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Vanguard Mega Cap Growth ETF nearer its low. Which is the better fit depends on your goals.
| ASND | MGK | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $92.06 |
52-Week Low | $163.32 | $70.70 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MGK, the Vanguard Mega Cap Growth ETF, trades at $89.06, up 0.52% today, with a bullish technical signal driven by moving averages. The ETF focuses on large-cap U.S. growth stocks, heavily concentrated in technology and consumer discretionary sectors. A 1:5 stock split occurred on April 21, 2026, and a $0.08 dividend is scheduled for June 30, 2026. Recent news highlights its low expense ratio of 0.05% and potential inclusion of SpaceX, enhancing its growth appeal.
Outlook remains positive due to strong mega-cap tech earnings and historical market outperformance. Key risks include high concentration in top holdings and sector-specific volatility. Investors benefit from cost efficiency and exposure to leading growth companies, but should monitor valuation levels and broader market trends for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Vanguard Mega Cap Growth ETF
MGK is an ETF that seeks to track the performance of the CRSP US Mega Cap Growth Index. It provides a low-cost, diversified exposure to the largest growth companies in the U.S. stock market. The fund is composed of mega-cap stocks that exhibit key growth factors, including high expected long-term earnings growth, high historical sales and earnings growth, and high return on assets. MGK is typically used by investors seeking long-term capital appreciation from market-leading firms.
Read more on MGK →
